Pharming Group N.V. 0QCO.IL Stock
Pharming Group N.V. Price Chart
Pharming Group N.V. 0QCO.IL Financial and Trading Overview
| Pharming Group N.V. stock price | 1.01 EUR |
| Previous Close | 1.11 EUR |
| Open | 1.13 EUR |
| Bid | 1.09 EUR x 0 |
| Ask | 1.15 EUR x 0 |
| Day's Range | 1.12 - 1.13 EUR |
| 52 Week Range | 0.66 - 1.42 EUR |
| Volume | 9.65K EUR |
| Avg. Volume | 1.46M EUR |
| Market Cap | 735.77M EUR |
| Beta (5Y Monthly) | 0.878544 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0QCO.IL Valuation Measures
| Enterprise Value | 712.32M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.6506119 |
| Price/Book (mrq) | 3.6161292 |
| Enterprise Value/Revenue | 3.534 |
| Enterprise Value/EBITDA | -763.469 |
Trading Information
Pharming Group N.V. Stock Price History
| Beta (5Y Monthly) | 0.878544 |
| 52-Week Change | 61.68% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.42 EUR |
| 52 Week Low | 0.66 EUR |
| 50-Day Moving Average | 1.09 EUR |
| 200-Day Moving Average | 1.12 EUR |
0QCO.IL Share Statistics
| Avg. Volume (3 month) | 1.46M EUR |
| Avg. Daily Volume (10-Days) | 690.81K EUR |
| Shares Outstanding | 656.35M |
| Float | 599.72M |
| Short Ratio | N/A |
| % Held by Insiders | 2.29% |
| % Held by Institutions | 17.74% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 0.1:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -0.99% |
| Operating Margin (ttm) | -3.036% |
| Gross Margin | 91.68% |
| EBITDA Margin | -0.46% |
Management Effectiveness
| Return on Assets (ttm) | -0.93% |
| Return on Equity (ttm) | -1.014% |
Income Statement
| Revenue (ttm) | 201.55M EUR |
| Revenue Per Share (ttm) | 0.32 EUR |
| Quarterly Revenue Growth (yoy) | -8.69% |
| Gross Profit (ttm) | 188.06M EUR |
| EBITDA | -933000 EUR |
| Net Income Avi to Common (ttm) | -1995000 EUR |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 184.78M EUR |
| Total Cash Per Share (mrq) | 0.29 EUR |
| Total Debt (mrq) | 170.4M EUR |
| Total Debt/Equity (mrq) | 85.48 EUR |
| Current Ratio (mrq) | 4.509 |
| Book Value Per Share (mrq) | 0.31 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -936000 EUR |
| Levered Free Cash Flow (ttm) | -1643375 EUR |
Profile of Pharming Group N.V.
| Country | United Kingdom |
| State | N/A |
| City | Leiden |
| Address | Darwinweg 24 |
| ZIP | 2333 CR |
| Phone | 31 71 524 7400 |
| Website | https://www.pharming.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 332 |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Q&A For Pharming Group N.V. Stock
What is a current 0QCO.IL stock price?
Pharming Group N.V. 0QCO.IL stock price today per share is 1.01 EUR.
How to purchase Pharming Group N.V. stock?
You can buy 0QCO.IL shares on the IOB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pharming Group N.V.?
The stock symbol or ticker of Pharming Group N.V. is 0QCO.IL.
Which industry does the Pharming Group N.V. company belong to?
The Pharming Group N.V. industry is Biotechnology.
How many shares does Pharming Group N.V. have in circulation?
The max supply of Pharming Group N.V. shares is 783.85M.
What is Pharming Group N.V. Price to Earnings Ratio (PE Ratio)?
Pharming Group N.V. PE Ratio is now.
What was Pharming Group N.V. earnings per share over the trailing 12 months (TTM)?
Pharming Group N.V. EPS is -0.02 EUR over the trailing 12 months.
Which sector does the Pharming Group N.V. company belong to?
The Pharming Group N.V. sector is Healthcare.